a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10706742		
Filing Date		2003-11-12		
First Named Inventor	Hans	F. van Rietschote		
Art Unit		2187		
Examiner Name	Farrol	kh, Hashem		
Attorney Docket Number		5760-16400		

			Remove			
Examiner Initial*	Cite No Patent Number		Kind Code ¹	Kind Code ¹ Issue Date Name of Patentee or A of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6704925		2004-03-09	Bugnion	
	2	6711672	. 2004-03-23 Agesen		Agesen	
	3	3 6725289 2004-04-20		2004-04-20	Waldspurger et al	
	4	6735601		2004-05-11	Subrahmanyam	
	5	6785886		2004-08-31	Lim et al	
	6	6789156		2004-09-07 Waldspurger		
	7	6961941		2005-11-01	Nelson et al	
	8	6961806		2005-11-01	Agesen et al	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10706742		
Filing Date		2003-11-12		
First Named Inventor	Hans	F. van Rietschote		
Art Unit		2187		
Examiner Name	Farrol	kh, Hashem		
Attornou Docket Number		5760 16400		

	9	7069413		2006-06-27 Agesen et al							
	10	7082598		2006-07	-25	Leetal					
	11	7089377		2006-08	1-08	Chen					
	12	7111086		2006-09	006-09-19 Ecoleston et al						
	13	7111145		2006-09	i-19	Chen et al					
	14	7111481		2006-06	1-26	Green et al					
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*			Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines whe ges or Rele				
	1										
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
	FOREIGN PATENT DOCUMENTS Remove										
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or V	vhere Rel	or Relevan	TK

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10706742	
iling Date		2003-11-12	
irst Named Inventor Hans		F. van Rietschote	
Art Unit		2187	
xaminer Name Farrol		kh, Hashem	
Harman Davidski Musekan		5760 16400	

	1								
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
				NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Cite Initials* Cite Initial								T6	
	1								
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE									
Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant									

See for Codes of USPTO Platent Documents at year, USPTO, DOLL or MEPP 071.04. * Enter office an all issued for a document, by the ho-letter code (WIPO Standard ST3, 3. * Projection Standard ST3, 4. * Projection ST3, 4.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10706742
Filing Date		2003-11-12
First Named Inventor Hans		F. van Rietschote
Art Unit		2187
Examiner Name Farrol		kh, Hashem
Attorney Docket Number		5760-16400

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make the	he appropriate selection(s):
---------------	----------	----------------------	------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Lawrence J. Merkel/	Date (YYYY-MM-DD)	2006-11-22
Name/Print	Lawrence J. Merkel	Registration Number	41191

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2211-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.